Breast Ductal Carcinoma In Situ
Conditions
Brief summary
This randomized phase III trial studies radiation therapy to see how well it works with or without trastuzumab in treating women with ductal carcinoma in situ who have undergone lumpectomy. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether radiation therapy is more effective with or without trastuzumab in treating ductal carcinoma in situ.
Detailed description
PRIMARY OBJECTIVES: I. To determine the value of trastuzumab given during radiation therapy (RT) compared to RT alone in preventing subsequent occurrence of ipsilateral breast cancer recurrence, ipsilateral skin cancer recurrence, or ipsilateral ductal carcinoma in situ (IIBCR-SCR-DCIS) in women with human epidermal growth factor receptor 2 (HER2)-positive DCIS resected by lumpectomy. SECONDARY OBJECTIVES: I. Determine the value of trastuzumab given during RT compared to RT alone in prolonging invasive or DCIS disease-free survival (IDFS)-DCIS. II. Determine the value of trastuzumab given during RT compared to RT alone in increasing invasive or DCIS recurrence-free interval. III. Determine the value of trastuzumab given during RT compared to RT alone in improving regional or distant recurrence. IV. Determine the value of trastuzumab given during RT compared to RT alone in improving the incidence of contralateral invasive or DCIS breast cancer. V. Determine the value of trastuzumab given during RT compared to RT alone in improving survival. VI. To explore the effect of trastuzumab on ovarian function. TERTIARY OBJECTIVES: I. To determine if the benefit of trastuzumab added to RT will be significantly higher in v-myc avian myelocytomatosis viral oncogene homolog (cMYC)-amplified tumors than in the cMYC non-amplified subset. II. To determine if the benefit of trastuzumab added to RT will be less in tumors with mutations in the phosphatidylinositol 3 (PI3) kinase gene than in tumors without PI3 kinase gene mutations. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients undergo standard whole breast irradiation (WBI) over 5-6 weeks. ARM II: Patients receive trastuzumab intravenously (IV) over 30-90 minutes once in weeks 1 and 4. Patients also undergo WBI as in Arm I. After completion of study treatment, patients are followed up every 6 months for 5 years and then every 12 months for 5 years.
Interventions
OTHERLaboratory Biomarker Analysis
Correlative studies
BIOLOGICALTrastuzumab
Given IV
RADIATIONWhole Breast Irradiation
Undergo standard whole breast irradiation
Sponsors
NRG Oncology
National Cancer Institute (NCI)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The patient must have consented to participate and must have signed and dated an appropriate Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines for the study treatment and for the pre-entry tumor block submission for HER2 testing and B-43 correlative studies * Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (0 = fully active, able to carry on all pre-disease performance without restriction; 1 = restricted in physically strenuous activity but ambulatory) * On histologic examination, the tumor must be ductal carcinoma in situ (DCIS) (patients with mixed DCIS and lobular carcinoma in situ \[LCIS\] are eligible) * The DCIS must be HER2-positive as determined by central testing * Estrogen and/or progesterone receptor status must be determined prior to randomization (patients with DCIS that is hormone receptor positive or negative are eligible) * All DCIS must have been resected by lumpectomy * The margins of the resected specimen must be histologically free of DCIS; for patients in whom pathologic examination demonstrates DCIS present at the line of resection, re-excision(s) may be performed to obtain clear margins (patients who require mastectomy are not eligible) * If axillary staging is performed, nodal staging must be pN0, pN0(i-), pN0(i+) which is defined as isolated tumor cells =\< 0.2 mm, regardless of the method of detection, i.e., immunohistochemistry (IHC) or hematoxylin & eosin (H&E), pN0(mol-), or pN0(mol+); note: axillary staging is not required * The interval between the last surgery for excision of DCIS (lumpectomy or re-excision of lumpectomy margins) and randomization must be no more than 120 days
Exclusion criteria
* Invasive (including microinvasion staged as T1mic) breast cancer (patients with DCIS suspicious for microinvasion, but not confirmed, are eligible) * Nodal staging of pN1 (including pN1mi) (note: axillary staging is not required) * DCIS present in more than one quadrant (multicentric) * Masses or clusters of calcification that are clinically or mammographically suspicious unless biopsied and proven to be benign (if DCIS is found, the patient is eligible if the DCIS was in the same quadrant of the ipsilateral breast and was resected with clear margins) * Contralateral breast cancer (including DCIS) * Whole breast irradiation administered before randomization (partial breast irradiation is prohibited) * Prior history of breast cancer, including DCIS (patients with a history of LCIS are eligible) * Prior anthracycline chemotherapy for any malignancy * Cardiac disease that would preclude the use of the drugs included in the B-43 treatment regimens; this includes but is not confined to: * Active cardiac disease: * Angina pectoris that requires the use of anti-anginal medication; * Ventricular arrhythmias except for benign premature ventricular contractions (PVCs) controlled by medication; * Conduction abnormality requiring a pacemaker; * Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication; and * Clinically significant valvular disease * History of cardiac disease: * Myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of left ventricular (LV) function; * Documented congestive heart failure; or * Documented cardiomyopathy * Uncontrolled hypertension, i.e., systolic blood pressure \[BP\] greater than 180 mm/Hg and/or diastolic BP greater than 100 mm/Hg (patients with hypertension that is well controlled on medication are eligible) * Other nonmalignant systemic disease that would preclude a patient from receiving trastuzumab or radiation therapy or would prevent prolonged follow-up * Other malignancies unless the patient is considered to be disease-free for 5 or more years prior to randomization and is deemed by her physician to be at low risk for recurrence; patients with the following cancers are eligible if diagnosed and treated within the past 5 years: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinoma of the skin * Pregnancy or lactation at the time of study entry (note: pregnancy testing according to institutional standards should be performed for women of child-bearing potential) * Administration of any investigational agent within 30 days before study entry
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ipsilateral Invasive Breast Cancer, Ipsilateral Skin Cancer Recurrence, or Ipsilateral DCIS-Free Survival | 5 years | Patients who are free from Ipsilateral Invasive Breast Cancer, Ipsilateral Skin Cancer Recurrence or Ipsilateral DCIS as estimated by (1- cumulative incidence) x 100%. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Invasive or DCIS Recurrence-free Interval | 5 years | Cox proportional hazards models will be used to evaluate the effect of treatment on time to event. The distributions of time to event will be estimated by the Kaplan-Meier method for each treatment group and will be compared between treatments by simple and stratified log-rank tests. Compared across treatment arms using cumulative incidence functions.Percentage of patients who are invasive or DCIS recurrence free estimated by (1-cumulative incidence) x 100%. |
| Invasive Regional or Distant-Free Recurrence | 5 years | Percentage of patients who are free of invasive regional or distant recurrence as estimated by (1 - cumulative incidence) x 100%. |
| Invasive or DCIS Disease-free Survival | 5 years | Events for analysis of IDFS-DCIS include: local recurrence in the ipsilateral breast following lumpectomy, regional recurrence, distant recurrence, contralateral breast cancer, second primary cancer (other than squamous and basal cell carcinoma of the skin, melanoma in situ, and carcinoma in situ of the colon and cervix), or death from any cause prior to recurrence or second primary cancer. Invasive breast cancer, ipsilateral recurrence, and contralateral breast cancer will be compared across treatment arms using cumulative incidence functions. Percentage of patients by a Kaplan-Meier analysis who are free of invasive or DCIS disease |
| Overall Survival | 5 years | Percentage of patients surviving as estimated by a Kaplan-Meier |
| Incidence of Post-treatment Amenorrhea in Women Who Were Premenopausal at the Time of Study Entry Premenopausal at the Time of Study Entry | 18 months | Proportion of patients who were pre-menopausal at randomization and who self-reported as not having menstrual periods afterwards |
| Contralateral Breast Cancer (Invasive or DCIS) - Free Survival | 5 years | Percentage of patients free of Contralateral Breast Cancer (Invasive or DCIS) as estimated by (1- cumulative incidence) x 100%. |
Countries
Canada, Puerto Rico, South Korea, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Standard WBI Standard WBI (Radiation Therapy) | 1,008 |
| WBI, Trastuzumab WBI, trastuzumab (Radiation Therapy + Trastuzumab x 2 doses. Dose 1: 8 mg/kg IV Dose 2: 6 mg/kg IV-given 3 weeks after dose 1 | 1,006 |
| Total | 2,014 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | No follow up data mapped to Other. | 3 | 13 |
Baseline characteristics
| Characteristic | Standard WBI | WBI, Trastuzumab | Total |
|---|---|---|---|
| Age, Continuous | 56 years STANDARD_DEVIATION 9.3 | 56 years STANDARD_DEVIATION 8.7 | 56 years STANDARD_DEVIATION 9 |
| Race/Ethnicity, Customized Latino | 45 Participants | 47 Participants | 92 Participants |
| Race/Ethnicity, Customized Non-Latino | 925 Participants | 920 Participants | 1845 Participants |
| Race/Ethnicity, Customized Unknown | 38 Participants | 39 Participants | 77 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 5 Participants | 5 Participants | 10 Participants |
| Race (NIH/OMB) Asian | 33 Participants | 43 Participants | 76 Participants |
| Race (NIH/OMB) Black or African American | 59 Participants | 58 Participants | 117 Participants |
| Race (NIH/OMB) More than one race | 4 Participants | 1 Participants | 5 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 4 Participants | 4 Participants | 8 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 10 Participants | 10 Participants | 20 Participants |
| Race (NIH/OMB) White | 893 Participants | 885 Participants | 1778 Participants |
| Sex: Female, Male Female | 1008 Participants | 1006 Participants | 2014 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 11 / 1,005 | 10 / 993 |
| other Total, other adverse events | 292 / 998 | 254 / 990 |
| serious Total, serious adverse events | 3 / 998 | 9 / 990 |
Outcome results
Primary
Ipsilateral Invasive Breast Cancer, Ipsilateral Skin Cancer Recurrence, or Ipsilateral DCIS-Free Survival
Patients who are free from Ipsilateral Invasive Breast Cancer, Ipsilateral Skin Cancer Recurrence or Ipsilateral DCIS as estimated by (1- cumulative incidence) x 100%.
Time frame: 5 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm I (Standard WBI) | Ipsilateral Invasive Breast Cancer, Ipsilateral Skin Cancer Recurrence, or Ipsilateral DCIS-Free Survival | 95.1 percentage of patients event free |
| Arm II (WBI, Trastuzumab) | Ipsilateral Invasive Breast Cancer, Ipsilateral Skin Cancer Recurrence, or Ipsilateral DCIS-Free Survival | 96.1 percentage of patients event free |
Secondary
Contralateral Breast Cancer (Invasive or DCIS) - Free Survival
Percentage of patients free of Contralateral Breast Cancer (Invasive or DCIS) as estimated by (1- cumulative incidence) x 100%.
Time frame: 5 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm I (Standard WBI) | Contralateral Breast Cancer (Invasive or DCIS) - Free Survival | 97.9 percentage of patients event free |
| Arm II (WBI, Trastuzumab) | Contralateral Breast Cancer (Invasive or DCIS) - Free Survival | 98.4 percentage of patients event free |
Secondary
Incidence of Post-treatment Amenorrhea in Women Who Were Premenopausal at the Time of Study Entry Premenopausal at the Time of Study Entry
Proportion of patients who were pre-menopausal at randomization and who self-reported as not having menstrual periods afterwards
Time frame: 18 months
Population: All patients who reported being postmenopausal at randomization who later self-reported as yes or no to whether or not they had menstrual periods.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm I (Standard WBI) | Incidence of Post-treatment Amenorrhea in Women Who Were Premenopausal at the Time of Study Entry Premenopausal at the Time of Study Entry | 63 percentage of participants |
| Arm II (WBI, Trastuzumab) | Incidence of Post-treatment Amenorrhea in Women Who Were Premenopausal at the Time of Study Entry Premenopausal at the Time of Study Entry | 72 percentage of participants |
Secondary
Invasive or DCIS Disease-free Survival
Events for analysis of IDFS-DCIS include: local recurrence in the ipsilateral breast following lumpectomy, regional recurrence, distant recurrence, contralateral breast cancer, second primary cancer (other than squamous and basal cell carcinoma of the skin, melanoma in situ, and carcinoma in situ of the colon and cervix), or death from any cause prior to recurrence or second primary cancer. Invasive breast cancer, ipsilateral recurrence, and contralateral breast cancer will be compared across treatment arms using cumulative incidence functions. Percentage of patients by a Kaplan-Meier analysis who are free of invasive or DCIS disease
Time frame: 5 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm I (Standard WBI) | Invasive or DCIS Disease-free Survival | 88.4 percentage of patients event free |
| Arm II (WBI, Trastuzumab) | Invasive or DCIS Disease-free Survival | 90.6 percentage of patients event free |
Secondary
Invasive or DCIS Recurrence-free Interval
Cox proportional hazards models will be used to evaluate the effect of treatment on time to event. The distributions of time to event will be estimated by the Kaplan-Meier method for each treatment group and will be compared between treatments by simple and stratified log-rank tests. Compared across treatment arms using cumulative incidence functions.Percentage of patients who are invasive or DCIS recurrence free estimated by (1-cumulative incidence) x 100%.
Time frame: 5 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm I (Standard WBI) | Invasive or DCIS Recurrence-free Interval | 94.4 percentage of patients event free |
| Arm II (WBI, Trastuzumab) | Invasive or DCIS Recurrence-free Interval | 95.8 percentage of patients event free |
Secondary
Invasive Regional or Distant-Free Recurrence
Percentage of patients who are free of invasive regional or distant recurrence as estimated by (1 - cumulative incidence) x 100%.
Time frame: 5 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm I (Standard WBI) | Invasive Regional or Distant-Free Recurrence | 99.9 percentage of patients event free |
| Arm II (WBI, Trastuzumab) | Invasive Regional or Distant-Free Recurrence | 99.9 percentage of patients event free |
Secondary
Overall Survival
Percentage of patients surviving as estimated by a Kaplan-Meier
Time frame: 5 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm I (Standard WBI) | Overall Survival | 98.9 percentage of patients surviving |
| Arm II (WBI, Trastuzumab) | Overall Survival | 99.0 percentage of patients surviving |